A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 26, Issue 12, 2012, Pages 1437-1446

  Ansari, Marc ^a   Uppugunduri, Chakradhara Rao S ^a   Déglon, Julien ^b   Théorêt, Yves ^c   Versace, François ^b   Gumy Pause, Fabienne ^a   Ozsahin, Hulya ^a   Dayer, Pierre ^a   Desmules, Jules ^a   Daali, Youssef ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; MASS SPECTROMETRY; PATIENT MONITORING; STEM CELLS;

ANALYTICAL METHOD; BUSULFAN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; SIMPLE++; SIMPLIFIED METHOD; THERAPEUTIC DRUG MONITORING; WHOLE BLOOD;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84861312133     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6241     Document Type: Article

References (59)

1. G. W. Santos, P. J. Tutschka, R. Brookmeyer, R. Saral, W. E. Beschorner, W. B. Bias, H. G. Braine, W. H. Burns, G. J. Elfenbein, H. Kaizer, et al., Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 1983, 309, 1347.
2. R. A. Clift, C. D. Buckner, E. D. Thomas, W. I. Bensinger, R. Bowden, E. Bryant, H. J. Deeg, K. C. Doney, L. D. Fisher, J. A. Hansen, et al., Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994, 84, 2036.
3. A. Devergie, D. Blaise, M. Attal, J. D. Tigaud, J. P. Jouet, J. P. Vernant, P. Bordigoni, N. Ifrah, C. Dauriac, J. Y. Cahn, et al., Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995, 85, 2263.
4. S. Slavin, A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker, G. Cividalli, G. Varadi, M. Kirschbaum, A. Ackerstein, S. Samuel, A. Amar, C. Brautbar, O. Ben-Tal, A. Eldor, R. Or,. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91, 756.
5. A. V. Schattenberg, T. H. Levenga,. Differences between the different conditioning regimens for allogeneic stem cell transplantation. Curr. Opin. Oncol. 2006, 18, 667.
6. A. Cohen, A. N. Bekassy, A. Gaiero, M. Faraci, S. Zecca, A. Tichelli, G. Dini,. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008, 41 Suppl 2, S43.
7. M. Takahata, S. Hashino, K. Okada, M. Onozawa, K. Kahata, J. Sugita, A. Shigematsu, T. Kondo, S. Yamamoto, T. Endo, M. Nishio, Y. M. Ito, J. Tanaka, T. Koike, M. Asaka, M. Imamura,. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. Am. J. Hematol. 2010, 85, 243.
8. M. Hassan, P. Ljungman, P. Bolme, O. Ringden, Z. Syruckova, A. Bekassy, J. Stary, I. Wallin, N. Kallberg,. Busulfan bioavailability. Blood 1994, 84, 2144.
9. A. Srivastava, B. Poonkuzhali, R. V. Shaji, B. George, V. Mathews, M. Chandy, R. Krishnamoorthy,. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004, 104, 1574.
10. J. H. Dalle, D. Wall, Y. Theoret, M. Duval, L. Shaw, D. Larocque, C. Taylor, J. Gardiner, M. F. Vachon, M. A. Champagne,. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant. 2003, 32, 647.
11. L. Nguyen, D. Fuller, S. Lennon, F. Leger, C. Puozzo,. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004, 33, 979.
12. T. Schechter, Y. Finkelstein, J. Doyle, Z. Verjee, M. Moretti, G. Koren, L. L. Dupuis,. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2007, 13, 307.
13. M. Ansari, J. F. Lauzon-Joset, M. F. Vachon, M. Duval, Y. Theoret, M. A. Champagne, M. Krajinovic,. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010, 45, 261.
14. R. Malar, F. Sjoo, K. Rentsch, M. Hassan, T. Gungor,. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr. Transplant. 2011, 15, 580.
15. J. T. Slattery, J. E. Sanders, C. D. Buckner, R. L. Schaffer, K. W. Lambert, F. P. Langer, C. Anasetti, W. I. Bensinger, L. D. Fisher, F. R. Appelbaum, et al., Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995, 16, 31.
16. A. M. Bolinger, A. B. Zangwill, J. T. Slattery, D. Glidden, K. DeSantes, L. Heyn, L. J. Risler, B. Bostrom, M. J. Cowan,. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000, 25, 925.
17. J. S. McCune, T. Gooley, J. P. Gibbs, J. E. Sanders, E. W. Petersdorf, F. R. Appelbaum, C. Anasetti, L. Risler, D. Sultan, J. T. Slattery,. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002, 30, 167.
18. S. M. Hoy, K. A. Lyseng-Williamson,. Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr. Drugs 2007, 9, 271.
19. T. Madden, M. de Lima, N. Thapar, J. Nguyen, S. Roberson, D. Couriel, B. Pierre, E. J. Shpall, R. B. Jones, R. E. Champlin, B. S. Andersson,. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol. Blood Marrow Transplant. 2007, 13, 56.
20. J. S. McCune, J. P. Gibbs, J. T. Slattery,. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin. Pharmacokinet. 2000, 39, 155.
21. U. Schuler, S. Schroer, A. Kuhnle, J. Blanz, K. Mewes, I. Kumbier, B. Proksch, K. P. Zeller, G. Ehninger,. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 1994, 14, 759.
22. K. L. Johnson-Davis, G. A. McMillin, J. M. Juenke, C. D. Ford, F. B. Petersen,. Which dose of busulfan is best? Clin. Chem. 2010, 56, 1061.
23. W. K. Lai, C. P. Pang, L. K. Law, R. Wong, C. K. Li, P. M. Yuen,. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin. Chem. 1998, 44, 2506.
24. L. Embree, R. B. Burns, J. R. Heggie, G. L. Phillips, D. E. Reece, J. J. Spinelli, D. O. Hartley, N. J. Hudon, J. H. Goldie,. Gas-chromatographic analysis of busulfan for therapeutic drug monitoring. Cancer Chemother. Pharmacol. 1993, 32, 137.
25. M. H. Quernin, B. Poonkuzhali, Y. Medard, D. Dennison, A. Srivastava, R. Krishnamoorthy, M. Chandy, E. Jacqz-Aigrain,. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. J. Chromatogr. B 1999, 721, 147.
26. M. L. Snyder, J. C. Ritchie,. Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS/MS). Methods Mol. Biol. 2010, 603, 129.
27. M. Rauh, D. Stachel, M. Kuhlen, M. Groschl, W. Holter, W. Rascher,. Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children: validation of liquid chromatography tandem mass spectrometry method. Clin. Pharmacokinet. 2006, 45, 305.
28. M. D. Kellogg, T. Law, M. Sakamoto, N. Rifai,. Tandem mass spectrometry method for the quantification of serum busulfan. Ther. Drug Monit. 2005, 27, 625.
29. E. O. dos Reis, R. Vianna-Jorge, G. Suarez-Kurtz, E. L. Lima, A. Azevedo Dde,. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 1666.
30. D. R. Bunch, C. Heideloff, J. C. Ritchie, S. Wang,. A fast and simple assay for busulfan in serum or plasma by liquid chromatography-tandem mass spectrometry using turbulent flow online extraction technology. J. Chromatogr. B 2010, 878, 3255.
31. J. B. Courtney, R. Harney, Y. Li, G. Lundell, G. A. McMillin, G. Agarwal, J. M. Juenke, A. Mathew, R. Gonzalez-Espinoza, M. Fleisher, S. J. Salamone,. Determination of busulfan in human plasma using an ELISA format. Ther. Drug Monit. 2009, 31, 489.
32. J. M. Juenke, K. A. Miller, G. A. McMillin, K. L. Johnson-Davis,. An automated method for supporting busulfan therapeutic drug monitoring. Ther. Drug Monit. 2011, 33, 315.
33. P. M. Edelbroek, J. van der Heijden, L. M. Stolk,. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 2009, 31, 327.
34. T. Koal, H. Burhenne, R. Romling, M. Svoboda, K. Resch, V. Kaever,. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 2995.
35. S. Aburuz, J. Millership, J. McElnay,. Dried blood spot liquid chromatography assay for therapeutic drug monitoring of metformin. J. Chromatogr. B 2006, 832, 202.
36. G. la Marca, S. Malvagia, L. Filippi, P. Fiorini, M. Innocenti, F. Luceri, G. Pieraccini, G. Moneti, S. Francese, F. R. Dani, R. Guerrini,. Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J. Pharm. Biomed. Anal. 2008, 48, 1392.
37. A. J. Wilhelm, J. C. den Burger, A. Chahbouni, R. M. Vos, A. Sinjewel,. Analysis of mycophenolic acid in dried blood spots using reversed phase high performance liquid chromatography. J. Chromatogr. B 2009, 877, 3916.
38. R. Ter Heine, J. W. Mulder, E. C. van Gorp, J. F. Wagenaar, J. H. Beijnen, A. D. Huitema,. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis 2011, 3, 1093.
39. G. P. Hooff, R. J. Meesters, J. J. van Kampen, N. A. van Huizen, B. Koch, A. F. Al Hadithy, T. van Gelder, A. D. Osterhaus, R. A. Gruters, T. M. Luider,. Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate-a validated assay for the clinic. Anal. Bioanal. Chem. 2011, 400, 3473.
40. K. Hoogtanders, J. van der Heijden, M. Christiaans, P. Edelbroek, J. P. van Hooff, L. M. Stolk,. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J. Pharm. Biomed. Anal. 2007, 44, 658.
41. M. Barfield, N. Spooner, R. Lad, S. Parry, S. Fowles,. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J. Chromatogr. B 2008, 870, 32.
42. P. Hubert, J. J. Nguyen-Huu, B. Boulanger, E. Chapuzet, P. Chiap, N. Cohen, P. A. Compagnon, W. Dewe, M. Feinberg, M. Lallier, M. Laurentie, N. Mercier, G. Muzard, C. Nivet, L. Valat, E. Rozet,. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal - part II. J. Pharm. Biomed. Anal. 2007, 45, 70.
43. J. Deglon, A. Thomas, Y. Daali, E. Lauer, C. Samer, J. Desmeules, P. Dayer, P. Mangin, C. Staub,. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. J. Pharm. Biomed. Anal. 2011, 54, 359.
44. A. Thomas, J. Deglon, T. Steimer, P. Mangin, Y. Daali, C. Staub,. On-line desorption of dried blood spots coupled to hydrophilic interaction/reversed- phase LC/MS/MS system for the simultaneous analysis of drugs and their polar metabolites. J. Sep. Sci. 2010, 33, 873.
45. T. Higashi, T. Nishio, S. Uchida, K. Shimada, M. Fukushi, M. Maeda,. Simultaneous determination of 17alpha-hydroxypregnenolone and 17alpha-hydroxyprogesterone in dried blood spots from low birth weight infants using LC-MS/MS. J. Pharm. Biomed. Anal. 2008, 48, 177.
46. B. Boulanger, P. Chiap, W. Dewe, J. Crommen, P. Hubert,. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. J. Pharm. Biomed. Anal. 2003, 32, 753.
47. T. E. Murdter, J. Coller, A. Claviez, F. Schonberger, U. Hofmann, P. Dreger, M. Schwab,. Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin. Chem. 2001, 47, 1437.
48. P. Balasubramanian, A. Srivastava, M. Chandy,. Stability of busulfan in frozen plasma and whole blood samples. Clin. Chem. 2001, 47, 766.
49. A. Karstens, I. Krämer,. Chemical and physical stability of diluted busulfan infusion solutions. EJHP Sci. 2007, 13, 40.
50. H. Ehrsson, M. Hassan,. Binding of busulfan to plasma proteins and blood cells. J. Pharm. Pharmacol. 1984, 36, 694.
51. A. A. Alfazil, R. A. Anderson,. Stability of benzodiazepines and cocaine in blood spots stored on filter paper. J. Anal. Toxicol. 2008, 32, 511.
52. R. Fingerhut, R. Ensenauer, W. Roschinger, R. Arnecke, B. Olgemoller, A. A. Roscher,. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal. Chem. 2009, 81, 3571.
53. G. Liu, Q. C. Ji, M. Jemal, A. A. Tymiak, M. E. Arnold,. Approach to evaluating dried blood spot sample stability during drying process and discovery of a treated card to maintain analyte stability by rapid on-card pH modification. Anal. Chem. 2011, 83, 9033.
54. F. Li, J. Zulkoski, D. Fast, S. Michael,. Perforated dried blood spots: a novel format for accurate microsampling. Bioanalysis 2011, 3, 2321.
55. N. Youhnovski, A. Bergeron, M. Furtado, F. Garofolo,. Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun. Mass Spectrom. 2011, 25, 2951.
56. W. Li, F. L. Tse,. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 2010, 24, 49.
57. L. B. Grochow, R. J. Jones, R. B. Brundrett, H. G. Braine, T. L. Chen, R. Saral, G. W. Santos, O. M. Colvin,. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 1989, 25, 55.
58. A. B. Leichtle, U. Ceglarek, H. Witzigmann, G. Gabel, J. Thiery, G. M. Fiedler,. Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients. J. Transplant. 2010, 201918.
59. T. Gordi, T. N. Hai, N. M. Hoai, M. Thyberg, M. Ashton,. Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur. J. Clin. Pharmacol. 2000, 56, 561.